

Table1. Baseline Characteristics of All 40 related Patients and Subgroups

Characteristic	All patient	Phase Ia				Phase Ib
	(n = 40)	1×10 ⁴ (±30%)/kg (n = 3)	5×10 ⁴ (±30%)/kg (n = 3)	1×10 ⁵ (±30%)/kg (n = 3)	1×10 ⁵ (±30%)/kg (n = 3)	(n = 31)
Median age (range), years	32(18,72)	40(28,72)	56(53,57)	29 (18,31)		32(18,67)
Male, No. (%)	26(65.0)	2(66.6)	2(66.6)	3 (100)		20(64.5)
Disease type,No. (%)						
T-ALL/LBL	35(87.5)	3(100)	2(66.7)	3 (100)		27(87.1)
SS	1(2.5)	0	1(33.3)	0		0
MEITL	1(2.5)	0	0	0		1(3.2)
CTCL	1(2.5)	0	0	0		1(3.2)
HSTCL	1(2.5)	0	0	0		1(3.2)
NK/T cell lymphoma	1(2.5)	0	0	0		1(3.2)
BM blasts at enrollment (by						
>25	11(27.5)	1(33.3)	1(33.3)	2(66.7)		7(22.6)
5-25	5(12.5)	0	1(33.3)	0		4(12.9)
<5	24(60.0)	2(66.7)	1(33.3)	1(33.3)		20(64.5)
EMD, No. (%)						
CNSL	10(25)	1(33.3)	1(33.3)	1(33.3)		7(22.6)
CNS1	7	1	0	1		5
CNS2	3	0	1	0		2
Mediastinal mass	4(10)	1(33.3)	1(33.3)	1(33.3)		1(3.2)
Bulky disease(>7cm)	4(10)	0	0	0		4(12.9)
Diffused	25(62.5)	2(66.7)	2(66.7)	2(66.7)		19(61.3)
Other	3(7.5)	0	0	0		3(9.7)
Median lines of therapy (range)	3(2,4)	2(2,3)	2(2,3)	3(3,4)		3(2,4)
Refractory disease,No. (%)	4(10)	0	0	0		4(12.9)
Prior autologous transplantation,No. (%)	5(12.5)	0	1(33.3)	1(33.3)		3(14.3)
Prior allogeneic transplantation,No. (%)	17(42.5)	1(33.3)	0	2(66.7)		14(45.2)
Source of CAR-T cells,No. (%)						
Patient	23(57.5)	2(66.7)	3(100)	1(33.3)		17(54.8)
Previous alloSCT donor	17(42.5)	1(33.3)	0	2(66.7)		14(45.2)
Donor types						
MRD	4(23.5)	0	0	0		4(28.6)
MUD	3(17.7)	1(100)	0	1(50)		1(7.1)
HID	10(58.8)	0	0	1(50)		9(64.3)

Disease burden was measured before lymphodepletion by assessments of bone marrow and CSF morphologic features.EMD with imageologic examination.

Abbreviations: AlloSCT, allogeneic stem-cell transplantation; BM, bone Marrow; EMD, extramedullary disease; CNSL, central nervous system leukemia; CTCL, cutaneous T-cell

Lymphoma; HID, haploidentical donor; HSTCL, hepatosplenic T-cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; MRD, matched related donor; MUD, matched unrelated donor; SS, sézary syndrome; T-ALL/LBL, T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma;